These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 21303996)

  • 21. New therapies for castration-resistant prostate cancer.
    Longo DL
    N Engl J Med; 2010 Jul; 363(5):479-81. PubMed ID: 20818868
    [No Abstract]   [Full Text] [Related]  

  • 22. Sipuleucel-T in metastatic castration-resistant prostate cancer: profile report.
    Plosker GL
    BioDrugs; 2011 Aug; 25(4):255-6. PubMed ID: 21815700
    [No Abstract]   [Full Text] [Related]  

  • 23. Sipuleucel-T (Provenge(®))-Autopsy of an Innovative Paradigm Change in Cancer Treatment: Why a Single-Product Biotech Company Failed to Capitalize on its Breakthrough Invention.
    Jarosławski S; Toumi M
    BioDrugs; 2015 Oct; 29(5):301-7. PubMed ID: 26403092
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Special report: vaccines for the treatment of prostate cancer.
    Technol Eval Cent Assess Program Exec Summ; 2010 Apr; 24(6):1-2. PubMed ID: 20575182
    [No Abstract]   [Full Text] [Related]  

  • 25. [Promising on advanced cancer, several new drugs coming].
    Widmark A; Karlsson CT
    Lakartidningen; 2012 Feb 22-28; 109(8):416-9. PubMed ID: 22509668
    [No Abstract]   [Full Text] [Related]  

  • 26. A prostate cancer 'vaccine' under development.
    Mayo Clin Health Lett; 2009 Dec; 27(12):4. PubMed ID: 20082492
    [No Abstract]   [Full Text] [Related]  

  • 27. Advanced clinical states in prostate cancer.
    Cheng HH; Lin DW; Yu EY
    Urol Clin North Am; 2012 Nov; 39(4):561-71. PubMed ID: 23084531
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Degarelix (firmagon) for prostate cancer.
    Med Lett Drugs Ther; 2009 Oct; 51(1323):82-3. PubMed ID: 19838145
    [No Abstract]   [Full Text] [Related]  

  • 29. Putting Provenge in perspective.
    Moul JW
    Oncology (Williston Park); 2011 Mar; 25(3):255, 258. PubMed ID: 21548468
    [No Abstract]   [Full Text] [Related]  

  • 30. Prostate-specific antigen screening trials and prostate cancer deaths: the androgen deprivation connection.
    Haines IE; Gabor Miklos GL
    J Natl Cancer Inst; 2013 Oct; 105(20):1534-9. PubMed ID: 24092918
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sipuleucel-T (Provenge®) for castration-resistant prostate cancer.
    Sartor O
    BJU Int; 2012 Jul; 110(2 Pt 2):E105. PubMed ID: 22176510
    [No Abstract]   [Full Text] [Related]  

  • 32. Sipuleucel-T (Provenge): active cellular immunotherapy for advanced prostate cancer.
    McKarney I
    Issues Emerg Health Technol; 2007 Sep; (101):1-4. PubMed ID: 17763575
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge).
    Harzstark AL; Small EJ
    Expert Opin Biol Ther; 2007 Aug; 7(8):1275-80. PubMed ID: 17696825
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostate cancer vaccines in clinical trials.
    Lubaroff DM
    Expert Rev Vaccines; 2012 Jul; 11(7):857-68. PubMed ID: 22913261
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How does sipuleucel-T alter our clinical practice?
    George D
    BJU Int; 2010 Oct; 106(7):945-6. PubMed ID: 20931691
    [No Abstract]   [Full Text] [Related]  

  • 36. [Castration resistant prostate cancer 2011].
    Miller K
    Aktuelle Urol; 2011 Mar; 42(2):95-102. PubMed ID: 21437832
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sipuleucel-T for prostate cancer: the immunotherapy era has commenced.
    Buonerba C; Ferro M; Di Lorenzo G
    Expert Rev Anticancer Ther; 2011 Jan; 11(1):25-8. PubMed ID: 21166508
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostate cancer.
    Brody H
    Nature; 2015 Dec; 528(7582):S117. PubMed ID: 26672779
    [No Abstract]   [Full Text] [Related]  

  • 39. What happened to the Provenge (Sipuleucel-T) vaccine for hormone refractory prostate cancer?
    Moyad MA
    Urol Nurs; 2007 Jun; 27(3):256-7. PubMed ID: 17674606
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Survival analyses overview in hormone-refractory prostate cancer clinical trials in the prostate-specific antigen era.
    Sartor O
    Clin Genitourin Cancer; 2007 Dec; 5(7):420-1. PubMed ID: 18272022
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.